Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Overview
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Companies Involved in Therapeutics Development
Novartis AG
Pharmaleads SA
Stragen New Molecules
Theravance Biopharma Inc
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Drug Profiles
(sacubitril + valsartan) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-37 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Neprilysin for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STR-324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-0212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-0714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Dormant Products
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Discontinued Products
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalise or CD10 or MME or EC 3.4.24.11) - Product Development Milestones
Featured News & Press Releases
Nov 18, 2019: Promising results for Novartis’s Entresto in HFpEF sub-populations
Oct 01, 2019: Novartis entresto receives FDA approval for pediatric heart failure, helping to address critical unmet need for treatment options
Sep 02, 2019: Novartis’s heart failure drug Entresto presents mixed trial results
Sep 01, 2019: Novartis PARAGON-HF trial suggests Entresto benefit in HFpEF patients but rrowly misses primary endpoint
Aug 19, 2019: Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
Jul 29, 2019: PARAGON-HF study by Novartis misses primary goal
Jul 22, 2019: Critical heart drug too pricey for some Medicare patients
Mar 18, 2019: Compound improves heart failure biomarker even after hospitalization
Mar 16, 2019: Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
Mar 14, 2019: Novartis joins the Global Chagas Disease Coalition and also announces first multitiol, prospective, randomized study in people with chronic Chagas cardiomyopathy
Dec 03, 2018: Novartis announces new data that shows Entresto (sacubitril/valsartan) can be initiated both pre- or post-discharge with comparable safety and tolerability in patients with heart failure
Nov 21, 2018: Novartis heart failure treatment Entresto is awarded prestigious Prix Galien Cada innovative product award
Nov 13, 2018: Novartis reports positive results from PIONEER-HF trial
Nov 05, 2018: Novartis provides update on Entresto
Aug 25, 2018: Novartis announces new data that show Entresto (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Pharmaleads SA, H2 2019
Pipeline by Stragen New Molecules, H2 2019
Pipeline by Theravance Biopharma Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019